In brief

  • Big pharmaceutical companies are sourcing new drugs from Chinese biotech companies, according to Goldman.

  • Around $440 billion worth of drugs will lose patent protection by 2032, according to Richter.

  • Can Summit’s Keytruda duel prove that China-made drugs work in the West?

Read the original story “Goldman Sachs Says China Biotech Is Where Big Pharma Shops Now” by Darryn Pollock at no.beincrypto.com